Bulk Inquiry
cPEPCK inhibitor
Axon 1165
CAS:
628279-07-2
Purity:
98%
- Soluble in DMSO
- MF: C25H26FN5O3
- MW: 463.5
Description
cPEPCK inhibitor is a GTP-competitive inhibitor of human cytosolic phosphoenolpyruvate carboxykinase (cPEPCK/PEPCK) with reported low submicromolar IC50 values. It is used to study gluconeogenic enzyme regulation.
Cytosolic PEPCK catalyzes a key step in gluconeogenesis and is important in hepatic glucose production and metabolic control. This cPEPCK inhibitor is useful for enzyme assays and metabolic pathway studies.
Key Features
- GTP-competitive cPEPCK inhibitor
- Targets human cytosolic PEPCK/PEPCK-C
- Reported low submicromolar IC50 values
- Useful for gluconeogenesis pathway research
Applications
- PEPCK enzyme inhibition assays
- Gluconeogenesis research
- Glucose metabolism studies
- Metabolic disease pathway models
More Information
| Parent CAS No. | 628279-07-2 |
|---|---|
| Chemical Name | N-{4-[3-Butyl-1-(2-fluoro-benzyl)-2,6-dioxo-2,3,6,9-tetrahydro-1H-purin-8-ylmethyl]-phenyl}-acetamide |
| SMILES | N1(CC2C=CC=CC=2F)C(=O)C2N=C(CC3C=CC(NC(=O)C)=CC=3)NC=2N(CCCC)C1=O |
| MFCD | MFCD09998866 |
| InChi | InChI=1S/C25H26FN5O3/c1-3-4-13-30-23-22(24(33)31(25(30)34)15-18-7-5-6-8-20(18)26)28-21(29-23)14-17-9-11-19(12-10-17)27-16(2)32/h5-12H,3-4,13-15H2,1-2H3,(H,27,32)(H,28,29) |
| InChiKey | JHSHXKJSPVHPCJ-UHFFFAOYSA-N |
| CID | 447371 |
| Short Description | cPEPCK inhibitor |
cPEPCK inhibitor
GTP-competitive cPEPCK inhibitor
Gluconeogenesis
PEPCK
GTP-competitive
Type 2
GTP-competitive cPEPCK
Inhibitor
PEPCK enzyme inhibition assays
Gluconeogenesis research
Glucose metabolism studies
Metabolic disease pathway models
metabolism
enzyme pharmacology
drug discovery
CAS 628279-07-2
Axon Medchem
Axon 1165
Supplier
Vendor
References
- LH Foley et al. Modified 3-alkyl-1,8-dibenzylxanthines as GTP-competitive inhibitors of phosphoenolpyruvate carboxykinase. Bioorg. Med. Chem. Lett. 2003, 13(20), 3607-10.
- LH Foley et al. X-ray structures of two xanthine inhibitors bound to PEPCK and N-3 modifications of substituted 1,8-dibenzylxanthines. Bioorg. Med. Chem. Lett. 2003, 13(21), 3871-4.
- SL Pietranico et al. C-8 Modifications of 3-alkyl-1,8-dibenzylxanthines as inhibitors of human cytosolic phosphoenolpyruvate carboxykinase. Bioorg. Med. Chem. Lett. 2007, 17(14), 3835-9.
